Vascular BioSciences Will Present Results of “CAR Peptide Targeted Liposomes Loaded with an Admixture of Fasudil and DETA Nonoate for the Treatment of PAH”, and “A PAH Drug Ranking Strategy for Individualized Combination Therapy via Pulmonary Endoarterial Biopsy̶

Vascular BioSciences Announces Publication of “Intratracheally Administered Peptide-Modified Lipid Admixture Containing Fasudil and/or DETA NONOate Ameliorates Various Pathologies of Pulmonary Arterial Hypertension” Vascular BioSciences Announces Publication of Promising P

Vascular BioSciences Announces Publication of “A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy” in the Current Issue of The Open Respiratory Medicine Journal  Vascular BioSciences Announces Publication of “A Bi

Vascular BioSciences Announces Publication of “CAR Selectively Enhances the Pulmonary Vasodilatory Effect of Fasudil in a Microsphere Model of Pulmonary Hypertension” in the Current Issue of The Open Respiratory Medicine Journal Vascular BioSciences Announces Publicat

Vascular BioSciences Receives $2.7M STTR Fast-Track Grant for CAR Liposomes with VA Hospital of Northern California Vascular BioSciences will be collaborating with the VA Hospital of Northern California on the development of CAR liposomes for pulmonary arterial hypertension treatment

Vascular BioSciences Announces New Preclinical Research Results Demonstrating Improved Pulmonary Hypertension and Sepsis Survival with CAR Peptide CEO of Vascular BioSciences, David Mann, makes connection between current research and COVID-19 applications Goleta, CA – Vascular BioScie

FDA Grants Vascular BioSciences Humanitarian Use Device (HUD) Designation to the Endoarterial Biopsy Catheter for Group 1 Pulmonary Arterial Hypertension Humanitarian Use Device (HUD) designation from the U.S. Food and Drug Administration (FDA) for the Endoarterial Biopsy Catheter (EA

Vascular BioSciences Presented Results of CAR Peptide Targeted Augmentation of Chronic Prostanoid Treatment in PAH at the ATS Meeting in Dallas, Texas New data on beneficial effects of co-administration of CAR peptide with treprostinil in experimental pulmonary hypertension GOLETA — V

Vascular BioSciences Awarded $2 Million Phase II STTR Grant From NHLBI to Develop CAR Peptide as a Targeted Therapy for Pulmonary Hypertension Grant awarded in partnership with Brigham and Women’s Hospital, Harvard Medical School Durham, North Carolina – Vascular BioSciences (VB

Vascular BioSciences Awarded Up To $2.3 Million Fast-Track STTR Grant From NHLBI To Develop CAR Peptide For Pulmonary Hypertension Project to be Conducted in Collaboration with Brigham and Women’s Hospital, Harvard Medical School. Durham, North Carolina, August 15th, 2017 – Vascular B